“Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.”, J Addict Med, vol. 10, no. 4, pp. 236-43, 2016.
, “Utility of Targeted Gene Sequencing to Differentiate Myeloid Malignancies from other Cytopenic Conditions”, Blood Adv, 2023.
, , “Using electronic health record data for substance use Screening, Brief Intervention, and Referral to Treatment among adults with type 2 diabetes: Design of a National Drug Abuse Treatment Clinical Trials Network study.”, Contemp Clin Trials, vol. 46, pp. 30-38, 2016.
, “Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data.”, Brief Bioinform, vol. 12, no. 3, pp. 203-14, 2011.
, “Using Cross-Validation to Evaluate Predictive Accuracy of Survival Risk Classifiers Based on High-Dimensional Data”, Brief Bioinformatics, vol. 12, pp. 203-214, 2011.
, “Usefulness of the Atrial Emptying Fraction to Predict Maintenance of Sinus Rhythm After Direct Current Cardioversion for Atrial Fibrillation.”, Am J Cardiol, vol. 118, no. 9, pp. 1345-1349, 2016.
, “Use of the National Cancer Institute Community Cancer Centers Program Screening and Accrual Log to Address Cancer Clinical Trial Accrual”, J Oncol Pract, vol. 10, pp. e73-e80, 2014.
, “Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual.”, J Oncol Pract, vol. 10, no. 2, pp. e73-80, 2014.
, “Use of rhGH in children with chronic kidney disease: lessons from NAPRTCS.”, Pediatr Nephrol, vol. 22, no. 8, pp. 1195-204, 2007.
, “Use of rhGH in Children with Chronic Kidney Disease: Lessons from NAPRTCS”, Pediatr Nephrol, vol. 22, pp. 1195-1204, 2007.
, “Use of Opportunistic Clinical Data and a Population Pharmacokinetic Model to Support Dosing of Clindamycin for Premature Infants to Adolescents”, Clin Pharmacol Ther, vol. 96, pp. 429-437, 2014.
, “Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents.”, Clin Pharmacol Ther, vol. 96, no. 4, pp. 429-37, 2014.
, , “Use of low-dose tacrolimus and associated hypomagnesemia in the prevention of erectile dysfunction following prostatectomy for prostate cancer.”, Pharmacol Rep, vol. 68, no. 6, pp. 1154-1158, 2016.
, “Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-bli”, Lancet Infect Dis, vol. 16, no. 1, pp. 31-42, 2016.
, “Use of Biological Assignment in Hematopoietic Stem Cell Transplantation Clinical Trials”, Clin Trials, vol. 5, pp. 607-616, 2008.
, “Use of biological assignment in hematopoietic stem cell transplantation clinical trials.”, Clin Trials, vol. 5, no. 6, pp. 607-16, 2008.
, “Use of a prescription opioid registry to examine opioid misuse and overdose in an integrated health system.”, Prev Med, vol. 110, pp. 31-37, 2018.
, “Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.”, J Clin Oncol, p. JCO2003613, 2021.
, “Updated multivariate analyses of patient characteristics as predictors of survival in hormone-refractory prostate cancer patients treated with suramin”, Cancer Epidemiology, Biomarkers & Prevention, vol. 7, pp. 631-34, 1998.
, “Update from studies in pediatric liver transplantation.”, Transplant Proc, vol. 33, no. 7-8, pp. 3604-5, 2001.
, “Untitled”, 2000.
, “Untitled”, 2004.
, “Untitled”, 2001.